The role of cancer antigen 125 (CA 125), human epididymis protein 4 (HE4), soluble mezotelin related protein (SMRP), folate receptor alpha (FOLRA) in estimation of malignancy risk in pelvic masses

The Role of cancer antigen 125 (Ca 125), Human Epididymis Protein 4 (HE4), Soluble Mezotelin Related Protein (SMRP), Folate Receptor Alpha (FOLRα) in Estimation of Malignancy Risk in Pelvic Masses BACKGROUND: An adnexal mass is a common gynecologic problem and malignancy must be excluded for any mass that is not clearly benign. Since ovarian cancer is the most common cause of gynecologic cancer death. The differential diagnosis of benign and malignant neoplastic masses is important for referring the patient to the gynecologic oncologist. Use of serum biomarkers for the diagnosis of ovarian cancer is an active area of investigation. The aim of this study is researching the effectiveness of cancer antigen 125 (CA 125), human epididymis protein (HE4), soluble mesothelin related peptide (SMRP) and folate receptor alpha (FOLRα) to determine malignant ovarian masses. METHODS: Our research was performed between September 2014 and January 2017. Between 18 and 90 ages, 95 operated patients because of pelvic masses are included. Preoperatively CA 125, HE4, SMRP, FOLRα levels are measured for each patient and relationship between tumor marker levels and pathological reports is examined. RESULTS: HE4 and SMRP levels are found higher in malignant masses significantly. But CA 125 and FOLRα levels are not related with malignancy. CONCLUSİON: HE4 and SMRP can be used as a serum biomarker for prediction of ovarian cancer according to our study. However the data should be supported with more studies. Keywords: Pelvic Masses, Cancer Antigen 125 (Ca 125), Human Epididymis Protein 4 (HE4), Soluble Mezotelin Related Protein (SMRP), Folate Receptor Alpha (FOLRα)